<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081834</url>
  </required_header>
  <id_info>
    <org_study_id>CR017011</org_study_id>
    <secondary_id>28431754DIA3005</secondary_id>
    <nct_id>NCT01081834</nct_id>
  </id_info>
  <brief_title>The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2
      different doses of canagliflozin administered as monotherapy compared with placebo in
      patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Canagliflozin is a drug that is being tested to see if it may be useful in treating patients
      diagnosed with type 2 diabetes mellitus (T2DM). This is a randomized (study drug assigned by
      chance), double blind (neither the patient or the study doctor will know the name of the
      assigned treatment), parallel-group, 3 arm (patients will be assigned to 1 of 3 treatment
      groups) multicenter study to determine the efficacy, safety, and tolerability of
      canagliflozin (100 mg and 300 mg) compared to placebo (a capsule that looks like all the
      other treatments but has no real medicine) in patients diagnosed with T2DM who are not
      achieving an adequate response from diet and exercise to control their diabetes.
      Approximately 450 patients with inadequate glycemic control with diet and exercise will
      receive once-daily treatment with canagliflozin 100 mg or 300 mg once daily for 52 weeks or
      26 weeks of double-blind treatment with placebo followed by 26 weeks of sitagliptin 100 mg
      (sitagliptin is an antihyperglycemic agent that will allow patients randomized to the placebo
      group to improve glycemic control and remain in the study). Patients will participate in the
      study for approximately 60 to 68 weeks (referred to as the Main Study). The study will also
      include a High Glycemic Substudy in 50 to 100 patients with T2DM who have poorer glycemic
      control with diet and exercise. Patients in the substudy will be assigned to receive
      double-blind canagliflozin 100 mg or 300 mg for 26 weeks and the total duration of patient
      participatation in the substudy will be approximately 34 to 42 weeks. During treatment, if a
      patient's fasting blood sugar remains high despite treatment with study drug and
      reinforcement with diet and exercise, the patient will receive treatment with metformin
      (rescue therapy) consistent with local prescribing information. Study drug will be taken
      orally (by mouth) once daily before the first meal each day unless otherwise specified.
      Patients will take single blind placebo for 1 or 2 weeks (wks) before randomization to the
      Main Study or the High Glycemic Substudy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 26 (Main Study)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;7% at Week 26 (Main Study)</measure>
    <time_frame>Week 26</time_frame>
    <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight From Baseline to Week 26 (Main Study)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Baseline to Week 26 (Main Study)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;7% at Week 26 (High Glycemic Substudy)</measure>
    <time_frame>Week 26</time_frame>
    <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares mean percent change in triglycerides from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares mean percent change in HDL-C from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">678</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <description>One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)</description>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One matching placebo capsule orally once daily for 26 weeks (Main Study)</description>
    <arm_group_label>Placebo/Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)</description>
    <arm_group_label>Placebo/Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM

          -  Patients in the main study must have a Hemoglobin A1c (HbA1c) between &gt;=7% and &lt;=10%
             and a fasting plasma glucose (FPG) &lt;270 mg/dL (15 mmol/L)

          -  Patients in the High Glycemic Cohort Substudy must have an HbA1c between &gt;10% and
             &lt;=12% and a FPG &lt;=350 mg/dL (19.44 mmol/L)

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a
             severe hypoglycemic episode within 6 months before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northglenn</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perryopolis</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Horn</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viljandi</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeonju-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius Lt</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur N/A</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mex</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Makati</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marikina City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasay</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fajardo</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halfway</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcala De Henares</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pozuelo De Alarcon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skene</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Guatemala</country>
    <country>Iceland</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Costa Rica</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <results_first_submitted>April 15, 2013</results_first_submitted>
  <results_first_submitted_qc>April 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2013</results_first_posted>
  <disposition_first_submitted>April 24, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 26, 2012</disposition_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Canagliflozin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Hemoglobin A1c</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study evaluated the efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. The study was conducted between 08 February 2010 and 18 August 2011 and recruited patients from 90 study centers in 17 countries worldwide.</recruitment_details>
      <pre_assignment_details>678 patients were enrolled into the study; 587 patients in the main study and 91 patients in the high glycemic substudy. 584 patients in the main study and all 91 patients in the high glycemic substudy received at least one dose of study drug and were included in the modified intent-to-treat (mITT) analyses sets and the safety analyses sets.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Main Study: Placebo/Sitagliptin</title>
          <description>In the Main Study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
        </group>
        <group group_id="P2">
          <title>Main Study: Canagliflozin 100 mg</title>
          <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Main Study: Canagliflozin 300 mg</title>
          <description>In the Main Study, each patient received 300 mg of canagliflozin once daily for 52 weeks.</description>
        </group>
        <group group_id="P4">
          <title>High Glycemic Substudy: Canagliflozin 100 mg</title>
          <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks only. No patients received treatment during the period Week 26 to Week 52.</description>
        </group>
        <group group_id="P5">
          <title>High Glycemic Substudy: Canagliflozin 300 mg</title>
          <description>In the High Glycemic Substudy, each patient received 300 mg of canagliflozin once daily for 26 weeks only. No patients received treatment during the period Week 26 to Week 52.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Period: Baseline to Week 26</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="197"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="172"/>
                <participants group_id="P3" count="175"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to take rescue therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of efficacy on rescue therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Period: Week 26 to Week 52</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155">5 pts discontinued on last day of core: lack of efficacy on rescue (2), not specified (NS) (3).</participants>
                <participants group_id="P2" count="170">2 pts discontinued on last day of core: adverse event (AE) (1), protocol violation (PV) (1).</participants>
                <participants group_id="P3" count="170">5 pts discontinued last day of core: AE (1), lost f/u (1), PV (1), NS (1), physician decision (1).</participants>
                <participants group_id="P4" count="0">The treatment duration for the High Glycemic Substudy was 26 weeks only.</participants>
                <participants group_id="P5" count="0">The treatment duration for the High Glycemic Substudy was 26 weeks only.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="165"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to take rescue therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Creatinine or eGFR withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of efficacy on rescue therapy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Main Study: Placebo/Sitagliptin</title>
          <description>In the Main Study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
        </group>
        <group group_id="B2">
          <title>Main Study: Canagliflozin 100 mg</title>
          <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Main Study: Canagliflozin 300 mg</title>
          <description>In the Main Study, each patient received 300 mg of canagliflozin once daily for 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>High Glycemic Substudy: Canagliflozin 100 mg</title>
          <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
        </group>
        <group group_id="B5">
          <title>High Glycemic Substudy: Canagliflozin 300 mg</title>
          <description>In the High Glycemic Substudy, each patient received 300 mg of canagliflozin once daily for 26 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="192"/>
            <count group_id="B2" value="195"/>
            <count group_id="B3" value="197"/>
            <count group_id="B4" value="47"/>
            <count group_id="B5" value="44"/>
            <count group_id="B6" value="675"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="549"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="10.88"/>
                    <measurement group_id="B2" value="55.1" spread="10.83"/>
                    <measurement group_id="B3" value="55.3" spread="10.17"/>
                    <measurement group_id="B4" value="49.7" spread="11.12"/>
                    <measurement group_id="B5" value="48.8" spread="10.92"/>
                    <measurement group_id="B6" value="54.5" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>AUSTRIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COLOMBIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESTONIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GUATEMALA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICELAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LITHUANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAYSIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MEXICO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHILIPPINES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH AFRICA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH KOREA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWEDEN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 26 (Main Study)</title>
        <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the Main Study, each patient recieved matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the Main Study, each pateint received 300 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 26 (Main Study)</title>
          <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.065"/>
                    <measurement group_id="O2" value="-0.77" spread="0.065"/>
                    <measurement group_id="O3" value="-1.03" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.091</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.088</ci_lower_limit>
            <ci_upper_limit>-0.729</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.091</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.342</ci_lower_limit>
            <ci_upper_limit>-0.985</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)</title>
        <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the High Glycemic Substudy, no patients received placebo.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the High Glycemic Substudy, each pateint received 300 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)</title>
          <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-2.13" spread="0.220"/>
                    <measurement group_id="O3" value="-2.56" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;7% at Week 26 (Main Study)</title>
        <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the Main Study, each patient recieved matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the Main Study, each pateint received 300 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;7% at Week 26 (Main Study)</title>
          <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="44.5"/>
                    <measurement group_id="O3" value="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.10</ci_lower_limit>
            <ci_upper_limit>9.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>14.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.14</ci_lower_limit>
            <ci_upper_limit>26.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)</title>
        <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the Main Study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the Main Study, each pateint received 300 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)</title>
          <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" spread="2.448"/>
                    <measurement group_id="O2" value="-27.2" spread="2.412"/>
                    <measurement group_id="O3" value="-35.0" spread="2.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-35.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.420</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.22</ci_lower_limit>
            <ci_upper_limit>-28.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-43.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.402</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.06</ci_lower_limit>
            <ci_upper_limit>-36.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)</title>
        <description>The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the Main Study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the Main Study, each pateint received 300 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)</title>
          <description>The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" spread="4.204"/>
                    <measurement group_id="O2" value="-42.9" spread="3.763"/>
                    <measurement group_id="O3" value="-58.8" spread="3.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-49.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.629</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.12</ci_lower_limit>
            <ci_upper_limit>-36.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-64.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.616</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-75.02</ci_lower_limit>
            <ci_upper_limit>-52.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight From Baseline to Week 26 (Main Study)</title>
        <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the Main Study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the Main Study, each pateint received 300 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight From Baseline to Week 26 (Main Study)</title>
          <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.2"/>
                    <measurement group_id="O2" value="-2.8" spread="0.2"/>
                    <measurement group_id="O3" value="-3.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)</title>
        <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the Main Study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the Main Study, each pateint received 300 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)</title>
          <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.780"/>
                    <measurement group_id="O2" value="-3.34" spread="0.775"/>
                    <measurement group_id="O3" value="-5.04" spread="0.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-3.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.093</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.860</ci_lower_limit>
            <ci_upper_limit>-1.568</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-5.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.088</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.556</ci_lower_limit>
            <ci_upper_limit>-3.280</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Baseline to Week 26 (Main Study)</title>
        <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the Main study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the Main Study, each pateint received 300 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides From Baseline to Week 26 (Main Study)</title>
          <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="3.5"/>
                    <measurement group_id="O2" value="2.5" spread="3.3"/>
                    <measurement group_id="O3" value="-2.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.8</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-10.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.6</ci_lower_limit>
            <ci_upper_limit>-0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)</title>
        <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the Main Study, each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the Main Study, each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the Main Study, each pateint received 300 mg of canagliflozin once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)</title>
          <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.4"/>
                    <measurement group_id="O2" value="11.2" spread="1.4"/>
                    <measurement group_id="O3" value="10.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>6.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>6.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>9.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;7% at Week 26 (High Glycemic Substudy)</title>
        <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the High Glycemic Substudy, no patients received placebo.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the High Glycemic Substudy, each pateint received 300 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;7% at Week 26 (High Glycemic Substudy)</title>
          <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="17.4"/>
                    <measurement group_id="O3" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)</title>
        <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the High Glycemic Substudy, no patients received placebo.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the High Glycemic Substudy, each pateint received 300 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)</title>
          <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-81.7" spread="6.459"/>
                    <measurement group_id="O3" value="-86.3" spread="6.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)</title>
        <description>The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the High Glycemic Substudy, no patients received placebo.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the High Glycemic Substudy, each pateint received 300 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)</title>
          <description>The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-118" spread="10.179"/>
                    <measurement group_id="O3" value="-126" spread="9.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)</title>
        <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the High Glycemic Substudy, no patients received placebo.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the High Glycemic Substudy, each pateint received 300 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)</title>
          <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-3.0" spread="0.6"/>
                    <measurement group_id="O3" value="-3.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)</title>
        <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the High Glycemic Substudy, no patients received placebo.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the High Glycemic Substudy, each pateint received 300 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)</title>
          <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-4.47" spread="1.754"/>
                    <measurement group_id="O3" value="-4.97" spread="1.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)</title>
        <description>The table below shows the least-squares mean percent change in triglycerides from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the High Glycemic Substudy, no patients received placebo.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the High Glycemic Substudy, each pateint received 300 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)</title>
          <description>The table below shows the least-squares mean percent change in triglycerides from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.6" spread="7.4"/>
                    <measurement group_id="O3" value="-12.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)</title>
        <description>The table below shows the least-squares mean percent change in HDL-C from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>In the High Glycemic Substudy, no patients received placebo.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>In the High Glycemic Substudy, each patient received 100 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>In the High Glycemic substudy, each pateint received 300 mg of canagliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)</title>
          <description>The table below shows the least-squares mean percent change in HDL-C from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.4" spread="2.9"/>
                    <measurement group_id="O3" value="10.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported for the duration of the study; each patient participated in the study for approximately 52 weeks.</time_frame>
      <desc>The total number of adverse events listed in the &quot;Other (non-Serious) Adverse Events&quot; table are based upon a cut-off of greater than or equal to 5 percent of patients experiencing the adverse event in any treatment arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Main Study (Baseline to Week 26): Placebo</title>
          <description>Each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E2">
          <title>Main Study (Baseline to Week 26): Cana 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin (Cana) once daily for 52 weeks. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E3">
          <title>Main Study (Baseline to Week 26): Cana 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin (Cana) once daily for 52 weeks. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E4">
          <title>Main Study (Baseline to Week 52): Placebo/Sitagliptin</title>
          <description>Each patient received matching placebo once daily for 26 weeks and were then switched from placebo to 100 mg of sitagliptin once daily until Week 52. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E5">
          <title>Main Study (Baseline to Week 52): Cana 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin (Cana) once daily for 52 weeks. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E6">
          <title>Main Study (Baseline to Week 52): Cana 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin (Cana) once daily for 52 weeks. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E7">
          <title>High Glycemic Substudy (Baseline to Week 26): Cana 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin (Cana) once daily for 26 weeks. Data are only available for Baseline to Week 26.</description>
        </group>
        <group group_id="E8">
          <title>High Glycemic Substudy (Baseline to Week 26): Cana 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin (Cana) once daily for 26 weeks. Data are only available for Baseline to Week 26.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bacterial prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="69" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="197"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Franchise Medical Leader, Cardiovascular &amp; Metabolism Franchise</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>1-800-526-7736</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

